Podcasts about therapeutics

A non-invasive Alzheimer's therapy is moving closer to patients, and it could reshape how brain health is treated. In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer's therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito's HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer's care. Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer's patients and families! Resources: Connect with and follow Christian Howell on LinkedIn. Follow Cognito Therapeutics on LinkedIn and explore their website.

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Atossa Therapeutics CEO Steven Quayjoined Steve Darling from Proactive to discuss the continued advancement of the company's lead investigational therapy, (Z)-Endoxifen, and its potential applications across multiple breast cancer indications as well as certain rare diseases. The discussion highlighted the scientific foundation of the program, recent clinical data presentations, and key milestones expected in the months ahead. Quay explained that Atossa Therapeutics was founded with a clear mission focused on improving the prevention and treatment of breast cancer. Central to that strategy is the development of (Z)-Endoxifen, a therapy derived from decades of clinical experience and scientific understanding surrounding tamoxifen, one of the most widely prescribed treatments for hormone receptor-positive breast cancer. While tamoxifen has been a standard therapy for many years, its effectiveness depends on a patient's ability to metabolize the drug into its active form, Endoxifen. Quay noted that this process can vary significantly between individuals due to genetic differences and metabolic factors. Atossa's approach is to administer Endoxifen directly, potentially bypassing those limitations and providing more consistent therapeutic exposure across patients. According to Quay, clinical studies conducted to date have demonstrated encouraging signs of efficacy while maintaining what he described as a notably clean safety profile. The company believes the direct administration approach could offer meaningful advantages in both treatment and prevention settings. The CEO reviewed Atossa's clinical progress, noting that the company has successfully completed multiple Phase 2 clinical trials evaluating Endoxifen in various breast cancer settings. These studies have generated data supporting the continued advancement of the program and helping to define potential pathways toward later-stage development. The findings presented at ASCO generated considerable interest, particularly data suggesting that Endoxifen may remain active in breast cancers that have developed mutations commonly associated with resistance to endocrine therapies. Resistance to hormonal treatments remains a significant challenge in breast cancer management, and the possibility of maintaining therapeutic activity in resistant tumors could represent an important clinical opportunity. Quay noted that feedback from oncologists, researchers, and industry participants at ASCO was highly encouraging, particularly regarding the potential implications of the resistance-related findings. Management believes these observations could help differentiate Endoxifen from existing treatment options and support future development strategies. Looking ahead, Atossa plans to consolidate results from multiple ongoing and completed clinical programs to build a comprehensive dataset supporting future regulatory discussions. The company intends to engage with regulatory authorities and potential pharmaceutical partners as it evaluates the most effective path toward Phase 3 clinical development and eventual commercialization. #proactiveinvestors #nasdaq #atos #BreastCancer #Endoxifen #Biotech #Oncology #ClinicalTrials #CancerResearch #ASCO #DrugDevelopment #HealthcareInnovation

Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) executive chairman Dr Sotirios Stergiopoulos joined Proactive's Stephen Gunnion to discuss the appointment of Professor Ozgur Sahin as a Scientific Advisor to the company and the progress of lead cancer therapy AO-252. Stergiopoulos explained why Sahin, a leading expert in TACC3 biology, is a key addition as the company advances the programme. He also highlighted encouraging early clinical data, including signs of tumour regression with no safety concerns reported to date, and outlined plans to begin dosing patients with a new AO-252 formulation in July. For more interviews and market insights, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #CoiledTherapeutics #AO252 #PrecisionOncology #CancerResearch #Biotech #Oncology #ClinicalTrials #TACC3 #DrugDevelopment #HealthcareInnovation #CancerTreatment #MedicalResearch #Biotechnology #LifeSciences #ProactiveInvestors

We love to hear from our listeners. Send us a message.In episode 130 of Cell & Gene: The Podcast, Dr. Naji Gehchan, Chief Medical and Development Officer at Kyverna Therapeutics, joins Host Erin Harris to outline the company's mission to apply CAR T-cell therapy beyond oncology to treat severe autoimmune diseases, highlighting promising Phase 2 data from its investigational therapy, Miv-cel, in stiff person syndrome (SPS). Dr. Gehchan explains that Miv-cel works by deeply depleting pathogenic B cells and enabling a broad immune reset, differentiating it from conventional therapies that require ongoing management. As Kyverna advances a rolling BLA submission, Dr. Gehchan positions this milestone as potentially historic, both for SPS patients and for the broader cell therapy field, signaling an inflection point where CAR T could transform autoimmune disease care in the same way it has oncology.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.This episode is brought to you by:Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase) Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the AI Agent & Copilot Podcast, Giuseppe Ianni, AI Practice Lead and industry thought leader, is joined by Nandita Puri, PhD Candidate at Georgia Tech and founder of Illumia.bio. Puri discusses how AI is transforming drug discovery by creating massive therapeutic libraries, connecting fragmented biomedical knowledge, and dramatically accelerating research timelines. Their conversation explores the convergence of AI, structural biology, and life sciences. Key Takeaways AI Expands the Search Space for New Therapeutics: Traditional drug discovery focuses on identifying a single drug for a single target, but Puri argues that diseases are complex biological systems requiring broader approaches. Her team is building an AI-generated library of more than 10 billion molecules across multiple therapeutic modalities. By treating drug discovery as a combinatorics problem, researchers can explore vastly larger therapeutic possibilities. Connecting Fragmented Scientific Knowledge Accelerates Discovery: One of the biggest bottlenecks in pharmaceutical research is the fragmented nature of scientific information. Researchers often spend years reviewing hundreds of papers before forming a hypothesis. Puri describes how her team is integrating 60 to 70 public databases into a connected knowledge platform that links diseases, genes, proteins, pathways, and drug candidates. As she notes, "When we type a disease, we know exactly the gene, we exactly know the protein." This consolidation dramatically reduces research time and enables scientists to make more informed decisions earlier in the discovery process. AI Creates New Opportunities for Rare Disease Research: Rare diseases have historically been underserved because of the high costs and long timelines associated with traditional drug development. Puri says that bringing a drug to market can require "$1 billion and about 10 years." By shortening research cycles from years to months, AI lowers the barriers to investigating diseases that pharmaceutical companies may have previously avoided. This acceleration enables smaller teams to pursue treatments for conditions affecting fewer patients while increasing the likelihood that promising therapies can move forward to validation and clinical testing. Visit Cloud Wars for more.

Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-dependent diabetes — replacing the missing pancreatic function with living cells that sense glucose and respond in real time. Avraham sat down with Racheli to discuss how the technology works, what their animal trials showed, why IP is critical, the challenges of funding a biotech startup in wartime Israel, her advice for founders just getting started and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ betalin. Listen to all of the episodes at https://jmbdavis.com/podcast.

Send us Fan MailWhat if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world's first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilitiesSupport the show

Pancreatic cancer is a devastating diagnosis, and the statistics are alarming. According to the latest research, it's the third leading cause of cancer-related deaths in the US, with over 50,000 people losing their lives each year. The disease is particularly aggressive, with a survival rate of just six to seven months after diagnosis. In this episode, our guest, Dr. Greg Verdine, shares his insights on a promising new treatment that could reshape the way we approach pancreatic cancer. Dr. Verdine, a professor of chemistry at Harvard and CEO of LifeMine Therapeutics, discusses the challenges of treating pancreatic cancer, including its tendency to be asymptomatic until late stages and its resistance to chemotherapy. He explains how a new daily pill, currently in early trial stages, targets the cancer's genetic mutations and has shown promising results in extending patients' lifespans. The conversation delves into the complexities of pancreatic cancer, including its unique characteristics that make it difficult to treat. Dr. Verdine highlights the importance of this new treatment, which has the potential to double patients' lifespans and pave the way for further research. If you're interested in learning more about this breakthrough treatment and the future of pancreatic cancer research, tune in to this episode to hear Dr. Verdine's expert insights and the potential for a brighter outlook on this devastating disease.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of events shaping the industry, ranging from regulatory hurdles to strategic acquisitions and scientific breakthroughs. A significant milestone has been achieved by Outlook Therapeutics with its product Lytenava (bevacizumab), which recently won an appeal with the FDA for wet age-related macular degeneration treatment. This antibody therapy, aimed at VEGF inhibitors, marks a notable advancement in ophthalmology, potentially transforming management strategies for this debilitating condition. Monoclonal antibodies like Lytenava continue to underscore their importance in treating chronic diseases, offering hope for patients and setting benchmarks for similar therapeutic innovations. On a less favorable note, AstraZeneca encountered a setback when their breast cancer treatment camizestrant faced rejection from an FDA advisory committee. Despite robust phase 3 data for hormone receptor-positive breast cancer, the advisory committee's decision delays the drug's review process. This serves as a stark reminder of the stringent requirements oncology treatments must meet and highlights the critical need for comprehensive clinical data to ensure patient safety and drug efficacy in this competitive field. Amidst these developments, Astellas is proactively addressing upcoming patent expirations, particularly for Xtandi in 2026. The company has announced a five-year growth strategy focused on pipeline acquisitions, illustrating broader industry trends where diversifying portfolios through acquisitions and partnerships is crucial for maintaining competitiveness and delivering innovative therapies. Business development activities continue to be a highlight within the sector. Apogee Therapeutics and Blackstone Life Sciences have entered into a $1.3 billion royalty financing agreement to advance an eczema drug, underscoring ongoing investments in autoimmune treatments. Similarly, AGC Biologics' partnership with Teikoku Seiyaku on microbial CDMO services aims at advancing musculoskeletal therapies, showcasing how collaborations can leverage specialized manufacturing capabilities for therapeutic progress. Clinical trials also made headlines as Junshi Biosciences reported that its drug toripalimab met primary endpoints in phase 3 trials for non-small cell lung cancer perioperative treatment. This achievement underscores the growing influence of immunotherapies in oncology, promising improved surgical outcomes and enhancing their role within cancer treatment paradigms. Funding continues to play a pivotal role in sustaining innovation within the industry. Editas Medicine recently raised $125 million to propel its CRISPR-based gene therapy pipeline forward. Such financial backing is instrumental in transitioning promising therapies from preclinical stages to market readiness, ensuring that groundbreaking science translates into patient-accessible treatments. Regulatory landscapes remain dynamic, with ongoing discussions about updating COVID-19 vaccine formulations to target emerging subvariants. The FDA's commitment to adapting vaccine guidelines reflects a proactive stance in infectious disease management, crucial for maintaining vaccine efficacy against evolving pathogens. In acquisition news, Olympus' purchase of Bioprotect for $270 million adds biodegradable balloon spacer technology to its prostate cancer radiation therapy offerings. This acquisition highlights how medical device innovations can complement pharmaceutical approaches, enhancing treatment efficacy and patient quality of life. These developments collectively paint a vibrant picture of the biotech and pharmaceutical industries—a landscape where scientific advancements, regulatory challenges, strategic planning, and financial investments converge. The implications are far-reaching, potentially redefining treatment paradigms across various therapeutic areas as these sectors continue their pursuit of innovation and improved patient care outcomes. Navigating this landscape also involves addressing broader challenges such as policy shifts and pricing pressures within key markets like the United States. Companies must remain adaptable, balancing growth strategies with compliance demands amidst changing regulatory environments—a theme echoed by recent surveys indicating heightened pressure on healthcare firms to maintain profitability. Moreover, geopolitical considerations are influencing cross-border investments in biotechnology as policymakers debate strategies best suited for managing foreign influence—reflecting broader concerns about national security and economic competitiveness within this critical sector. As we continue monitoring these dynamic shifts within pharmaceuticals and biotechnology, it's evident that scientific innovation remains tightly interwoven with regulatory scrutiny and financial dynamics. The ongoing dance between these elements will undoubtedly shape future trajectories in healthcare advancements globally, promising new horizons in patient care while addressing pressing health challenges worldwide. That's all for today's episode of Pharma Daily—where we keep you informed on the latest developments driving progress within pharmaceuticals and biotechnology. Thank you for tuning in; until next time!Support the show

What does it really take to progress from bench science to leading a Biotech platform as Chief Scientific Officer? In this episode of Careers in Discovery, Daniel Tardiff, CSO at Camp4 Therapeutics, shares a candid look at building and scaling science inside an early‑stage biotech. From his foundations in RNA biology to advancing antisense programmes for haploinsufficiency-driven neurodevelopmental disorders, Dan unpacks how translational judgement is developed over time, not taught. Key takeaway: Career progression isn't about having perfect answers. It's about making credible decisions under uncertainty and bringing others with you as the science scales.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adapting to regulatory inconsistencies around rare disease drug approval frameworks in the U.S. and Europe.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

A conversation with Dr. Babak Kateb Find the video of this conversation at https://youtu.be/GbnIhjO_Af0 Find more at https://www.worldbrainmapping.org/

We love to hear from our listeners. Send us a message.In episode 129 of Cell & Gene: The Podcast, Host Erin Harris reconnects with Zachary Roberts, M.D., Ph.D., EVP of Research & Development and Chief Medical Officer at Allogene Therapeutics, to explore how allogeneic CAR-T is evolving from a scalability promise into an earlier-line, potentially curative intervention. Their conversation centers on the ALPHA3 trial, where MRD-guided treatment is redefining when and how CAR-T can be deployed, alongside broader implications for diagnostics, patient access, and the shift toward off-the-shelf therapies in community settings.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Send us Fan MailIn the time it will take you watch this episode, over 2,000 people around the world will die from diseases driven by arterial plaque. But what if we could actually remove the toxic cholesterol already trapped inside arteries?Today we're diving into one of the biggest unsolved problems in medicine and aging: how do you actually remove arterial plaque instead of merely slowing its progression?Cardiovascular disease remains the world's leading killer, despite decades of statins, anti-inflammatory drugs, and newer RNA-based therapies. Most existing treatments help manage cholesterol and reduce risk, but very few directly target the toxic debris already embedded inside plaques.But what if we could literally extract some of the most dangerous oxidized cholesterol molecules from the body?My guest today is Dr. Matthew ‘Oki' O'Connor, Ph.D. - CEO and Co-Founder of Cyclarity Therapeutics ( https://cyclaritytx.com/ ), a biotech company developing engineered cyclodextrin molecules designed to bind and remove 7-ketocholesterol, or 7KC - a toxic oxidized cholesterol strongly implicated in atherosclerosis, inflammation, plaque instability, and even broader age-related diseases.Just recently, the company presented first-in-human clinical data at the American Heart Association Vascular Discovery Scientific Sessions showing dose-dependent urinary excretion of 7KC - potentially the first clinical evidence that this toxic molecule can be safely mobilized and removed from the human body.We'll discuss what 7KC actually is, why oxidized cholesterol may be a root driver of cardiovascular disease, how engineered cyclodextrins work like molecular “sponges,” what the new human data really shows - and what it would mean if medicine could move from slowing plaque progression to truly reversing it.#HeartDisease #Atherosclerosis #Longevity #CardiovascularDisease #PlaqueReversal #AgingResearch #Biotech #Cholesterol #OxidizedCholesterol #7Ketocholesterol #Cyclarity #Healthspan #PrecisionMedicine #AIinBiotech #DrugDiscovery #PreventiveMedicine #Cardiology #AntiAging #Lifespan #MedicalInnovation #SENS #FoamCells #Plaque #HeartAttack #StrokePreventionSupport the show

This interview is disseminated on behalf of Cardiol Therapeutics Inc.In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis.Learn more: https://www.cardiolrx.comWatch the full YouTube interview here: https://youtu.be/NXkzgfWHQnAAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia 

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reflect on major themes and anticipated developments ahead of the upcoming American Diabetes Association (ADA) Scientific Sessions 2026.The discussion opens with Bellini congratulating Isaacs on receiving the ADA Outstanding Educator in Diabetes Award, prompting a conversation centered on Isaacs' forthcoming presentation, “Behind Every Number Is a Story: Transforming Diabetes Care and Education through Technology and Human Connection.” Isaacs reflects on the rapid evolution of diabetes technology over the last decade, from limited continuous glucose monitoring (CGM) access and the emergence of early automated insulin delivery (AID) systems to the integration of artificial intelligence into diabetes care, while emphasizing that successful care remains grounded in human connection and individualized patient experiences.The hosts then preview several therapeutic areas expected to dominate discussion at ADA, particularly the expanding pipeline of incretin-based therapies. Bellini and Isaacs discuss growing excitement surrounding GLP-1, GIP, and glucagon receptor agonists, including anticipated data from triple agonist agents such as retatrutide and emerging oral therapies like orforglipron. They highlight the significance of improved weight-loss efficacy in people with type 2 diabetes (T2D), broader cardiometabolic applications, and the increasing importance of treatment accessibility and affordability. The conversation also explores the expanding role of these therapies in addressing cardiovascular disease, chronic kidney disease, sleep apnea, osteoarthritis, and other obesity-related comorbidities.Technology advancements represent another major focus of the episode. Isaacs and Bellini discuss new CGM-driven insulin titration tools, including Dexcom's Smart Basal feature, designed to address therapeutic inertia among people with T2D using basal insulin. They also examine the growing role of CGM in broader patient populations and discuss evolving ADA recommendations supporting CGM access for any individual likely to benefit from the technology. The hosts express particular enthusiasm for the anticipated arrival of continuous ketone monitoring, including dual glucose-ketone sensors, and consider how these devices may transform diabetic ketoacidosis prevention and patient education, particularly for individuals with type 1 diabetes (T1D).The conversation also highlights continued innovation in insulin delivery systems and connected diabetes devices. Isaacs and Bellini discuss progress toward fully closed-loop AID systems, including ongoing studies evaluating meal-unannounced insulin delivery in T2D. They review emerging insulin pump technologies from Medtronic, including updates to the MiniMed platform and the integration of connected insulin pen systems with real-time CGM data through the MiniMed Go app. The hosts emphasize the importance of preserving therapeutic choice for people who prefer injections over pump therapy or who seek temporary alternatives to wearable devices.Toward the conclusion of the episode, both hosts preview their own ADA presentations. Isaacs discusses an upcoming session on inhaled insulin that will use simulated patient scenarios to explore shared decision-making and individualized therapy selection. Bellini highlights her session focused on skin complications related to diabetes technologies, including allergic reactions and adhesive-related challenges that can interfere with sustained device use. Together, they underscore the importance of addressing practical barriers to technology adoption while continuing to expand therapeutic and technological options for people living with diabetes.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

In this episode of Careers in Discovery, Adrian Gabriel Torres, Chief Scientific Officer at Aptadel Therapeutics, talks about developing RNA aptamer–based cancer therapies and leading scientific strategy in a preclinical biotech start-up. Adrian also shares his journey from academic research into industry, reflecting on the differences between academia and biotech, learning new skill sets, managing teams, and making career decisions along the way.

Rakhi Melvani, M.D., board-certified cornea and cataract and refractive surgeon at Gordon Schanzlin New Vision Institute, joins the Eye on Innovation podcast with host Carey Powers, M.B.A. to discuss innovative corneal treatments and how they're changing the way patients receive treatment. Their conversation explores the FDA approval of Epioxa, an epithelium-on corneal collagen cross-linking therapy to treat progressive keratoconus, as well as refractive surgery and dry eye therapies.   In this episode, learn about:  Ray tracing-based customization technology and how it's different from Lasik Collagen mimetic peptides and how they work ST100 and the patients that would benefit from it  RESOURCES:  Carey Powers: https://ois.net/carey-powers/  

In this episode of The Sunday Roast, Phil Carroll and Kevin Hornsby discuss the latest political and geopolitical developments impacting global markets, including UK election results, tensions in the Middle East and the wider effect on commodities and investor sentiment.The show also features an interview with Dr Sotirios Stergiopoulos from Coiled Therapeutics plc , discussing the company's oncology platform, progress around  AO-252  and its potential across multiple cancer indications.Later in the episode, Charles Archer joins the show alongside David Minchin from Halo Minerals Plc to discuss permitting progress, project development, financing strategy and future catalysts across the company's portfolio.00:00 - 00:05:32 Weekly News Roundup00:05:32 #COIL Interview00:38:38 #HALO Interview01:02:32 #EPP 01:04:15 #DGQ01:05:50 #KEN 01:07:44 #AEG Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a slew of advances in diabetes technology and treatments, starting with the US Food and Drug Administration (FDA)'s recent approval of the Tandem automated insulin delivery system for use during pregnancy in individuals with type 1 diabetes. The conversation centers on findings from the CIRCUIT trial, which demonstrated significant improvements in time in range among pregnant patients, a population historically challenging to manage because of stringent glycemic targets. Isaacs and Bellini review practical considerations from the study, including the use of continuous sleep mode to target tighter glucose ranges and proactive optimization of basal rates, correction factors, and carbohydrate ratios to improve outcomes. They emphasize that FDA approval now allows clinicians and manufacturers to openly discuss evidence-based best practices for pregnancy management using automated insulin delivery systems.The hosts also highlight the importance of clinician comfort with aggressive insulin automation during pregnancy, noting that increased basal modulation, suspensions, and automated adjustments should be expected as physiologic insulin needs fluctuate throughout gestation. Bellini stresses the importance of reducing patient burden while maintaining intensive glycemic management, tying this theme into Tandem's newly announced compatibility with the Dexcom G7 15-day sensor. Both hosts note strong patient enthusiasm for extending sensor wear time, framing reduced device maintenance as an important quality-of-life improvement even when the practical change appears modest.The discussion then shifts to immunotherapy in type 1 diabetes, focusing on the expanded approval of teplizumab to include children as young as 1 year old for delaying progression from stage 2 to stage 3 disease. Isaacs and Bellini underscore how broader eligibility may strengthen adoption of autoantibody screening among relatives of patients with type 1 diabetes. They review evidence showing that screening substantially lowers rates of diabetic ketoacidosis at diagnosis and discuss the broader clinical significance of delaying symptomatic disease onset, even when delays are shorter than the median duration reported in trials. The hosts note that many families value the possibility of a more gradual transition into insulin dependence, often requiring only minimal insulin therapy initially rather than presenting with severe metabolic decompensation.The conversation also addresses ongoing regulatory developments surrounding teplizumab for newly diagnosed stage 3 type 1 diabetes. Although the anticipated expedited review pathway has been withdrawn, the hosts remain optimistic about eventual approval, citing encouraging data and the growing role of precision medicine approaches in identifying patients most likely to benefit from immune intervention.To conclude the episode, Isaacs and Bellini examine a post hoc analysis from the SURMOUNT-5 trial comparing tirzepatide and semaglutide in adults with obesity and prediabetes. They discuss findings showing high rates of reversion to normoglycemia in both treatment groups, with tirzepatide demonstrating greater efficacy overall. The hosts frame these data within the broader movement to reconceptualize prediabetes as an earlier stage of type 2 diabetes and cardiovascular disease risk rather than a benign precursor state. They emphasize the potential value of earlier therapeutic intervention to prevent progression and reduce long-term cardiometabolic complications while also acknowledging the importance of maintaining multiple treatment options because of variability in medication tolerability and patient response.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.References1: Tandem Diabetes Care. Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes. April 27, 2026. Accessed May 8, 2026. https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-cares-control-iq-automated-insulin-delivery2: Sanofi. Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. April 22, 2026. Accessed May 8, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-32786503: Galindo RJ, Aronne LJ, Horn DB, et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. J Endocrinol Invest. Published online April 20, 2026. doi:10.1007/s40618-026-02895-3

Dr Simon Dean is an ophthalmologist based in New Zealand with a keen interest in optoelectronics. In 2007 he was awarded fellowship of the Royal Australian and New Zealand College of Ophthalmologists (FRANZCO). He completed fellowship training in the UK in oculoplastics and ocular oncology in Glasgow, followed by cataracts and anterior segment in Birmingham, UK, and the Bedford branch of Moorfields Eye Hospital. He also holds fellowship of the British Contact Lens Association (FBCLA) by examination. He completed his MSc in cataract and refractive surgery in 2009. Dr Dean was Head of Department at Manukau Superclinic for seven years, and consults privately through re:vision a boutique cataract and refractive clinic in Auckland. He was the Subject Leader for the RANZCO Optics exam team for 12 years and recently promoted within the College to Chair of the basic sciences and COPEM. Dr Dean is active in teaching and research and has designed and built a number of ophthalmic instruments, including a corneal collagen crosslinking device. He is inventor of the Photon Therapeutics device having built the first prototypes and coordinated the research to support this novel technology. When he is not accompanying his two boys to their many extracurricular activities, he can be found either on a mountain bike, climbing, or playing double bass in the St Matthews Chamber Orchestra. He is married to ocular surface research pioneer Professor Jennifer Craig.Check out Photon TherapeuticsCome check us out at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ashburton Eyecare⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/ashburton.eyecare/Instagram https://www.instagram.com/ryanoconnornz/  Instagram https://www.instagram.com/stagryan/  Twitter https://twitter.com/stagryan  Tik Tok @ryanstagoconnor  Facebook https://www.facebook.com/WaiKeto/  Blog https://stagryan.com/

In this episode of The Sunday Roast, Phil Carroll, Kevin Hornsby and Charles Archer discuss the latest global developments impacting markets, including geopolitical tensions in the Middle East and their effect on energy and investor sentiment.The show features interviews with Rift Helium, Solvonis Therapeutics plc, and Karelian Diamond Resources. Discussions cover helium exploration and market dynamics, advances in biotech and drug development strategy, and updates on diamond exploration and recent drilling progress.The episode wraps up with the latest market movers, fundraises, and commentary across key sectors.00:00 - 00:06:02 Weekly News Roundup00:06:02 #RIFT Interview00:47:38 #SVNS Interview01:16:25 #KDR Interview01:42:43 #DELT 01:43:26 #QDE 01:45:49 #AEG 01:47:34 #ONDO 01:51:24 #DELTA Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast. 

Send us Fan MailFor decades, Parkinson's patients have been offered only symptom management. No drug has ever slowed the disease itself. A small clinical stage biotech may be about to change that.Gene Mack, CEO, Gain Therapeutics joins host David E. Williams to discuss the science behind a potential first disease modifying therapy for Parkinson's, how AI is accelerating drug discovery, and what it takes to build a biotech in one of the toughest capital markets in years.

There are few neurodegenerative diseases as devastating as Huntington's. It's sometimes likened to having Parkinson's, ALS and Alzheimer's all at the same time, with symptoms that include progressive motor dysfunction, cognitive decline and behavioural change. It's also hereditary — if a person has the faulty gene that causes the disease, there's a 50 percent chance their children will have it, too. In the fall of 2025, however, scientists announced that, for the first time, they could reduce the progression of Huntington symptoms using a new gene therapy. While that clinical breakthrough came with several caveats, it also heralded a possible new paradigm for drug discovery. In this episode, we explore how this innovative therapy works and what it could mean for the treatment of other rare diseases.  Featured in this episode: Rachel Harding is an assistant professor in the department of pharmacology and toxicology at the University of Toronto and a principal investigator at the Structural Genomics Consortium. Her work on Huntington's disease has been recognized with major early-career awards, highlighting both scientific excellence and the potential patient impact of her research program. Further reading: Research is unravelling the mystery of what causes Huntington's disease, a devastating brain disease In a first, a gene therapy seems to slow Huntington disease “Best news” for Huntington's disease community comes with unanswered questions The Huntington's disease research pipeline World's first patient treated with personalized CRISPR gene editing therapy at Children's Hospital of Philadelphia Solve for X is brought to you by MaRS, North America's largest urban innovation hub and a registered charity. MaRS supports startups and accelerates the adoption of high-impact solutions to some of the world's biggest challenges. For more information, visit marsdd.com.

Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

This episode features Marwan G. Fakih, MD - Medical Oncologist, Professor, Department of Medical Oncology & Therapeutics Research, Deputy Director, City of Hope Comprehensive Cancer Center, Division Chief, GI Medical Oncology, Co-director, Gastrointestinal Cancer Program at City of Hope. Here he shares his thoughts around potentially screening younger patients, due higher rates of colon cancer. He also discusses the importance of educating patients to not overlook potential symptoms, clinical trials, and more.

Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate microRNAs to become metastatic. This is a systems-biology therapeutic approach that targets the entire survival network of a cell, making it independent of specific mutations or pathways and potentially applicable to the vast majority of solid tumors. Robert explains, "NUAgo is a technology company. We are developing what we define as short RNAs, and these are going to be cancer therapies that really target the survival system of a cancer. This survival system keeps the cancer alive. And instead of going after single components, pathways, or mutations as targeted therapies do, we're using short RNAs to reduce the expression of multiple essential survival genes. And when you get enough of these genes disrupted, the cancer cells can no longer maintain the system that keeps them alive. And at that point, the cell will activate a death response that eliminates the cancer cell by activating several cell death pathways simultaneously. So this is really a unique area in science, and we're developing this. It's a new modality. You see a lot of promise of this in the solid tumor patients."   "The platform that we're building has the potential to go across solid tumor markets. The recent IP that we're filing is for the 11 largest tumor markets from breast and lung, kidney, liver, and all the way down to the smaller, more lethal cancers in pancreas, ovarian, and other small cancers as well. So right now we think we can apply this to about 85% or 90% of the market."   "What we're doing is we take a step back. We're in fundamental biology. So this mechanism really goes back almost a billion years. I mean, fungi have the same mechanism. And so when we go after what are called survival genes, and they are essential for the survival of a cell, they deal with all kinds of cellular functions." #NUAgoTherapeutics #CancerResearch #Oncology #Biotechnology #PrecisionMedicine #RNATherapeutics #SystemsBiology #MedicalInnovation #HealthcareBreakthrough #CancerTreatment #SurvivalGenes #BiopharmaDevelopment NUAgotherapeutics.com Download the transcript here

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world.     This episode of the Business of Biotech is brought to you by Cytiva. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode, we explore the rapidly evolving field of regenerative medicine, focusing on a cutting-edge approach known as RPA (Regenerative Protein Array). Joined by leading medical experts, we break down how RPA differs from traditional therapies like PRP and stem cells, and how it leverages a complex network of proteins to support healing, recovery, and performance. The discussion covers real-world applications across elite athletes, aging populations, and neurocognitive conditions, while also addressing key questions around treatment frequency, safety, and effectiveness. Overall, this episode bridges the gap between emerging science and practical outcomes in modern regenerative care.Relevant links:Genesis Contact Information1-855-320-7559www.genesisregenerative.compatient-inquiry@genesisregenerative.comclinician-inquiry@genesisregenerative.com Dr. Jacobson Contact InformationMark Jacobson, M.D.Genesis Medical Director – MusculoskeletalMedical Imaging & Therapeutics, Lady Lake, FloridaFounder & Medical Directorwww.mitflorida.comDr. Bregman Contact InformationPeter Bregman, DPMGenesis Medical Director – Foot, Ankle, NeuropathyBregman Foot-Ankle & Nerve Center, Las Vegas, NVFounder & Medical Directorwww.bregmanfance.com Prof. Dr. Bankole Johnson Contact InformationProfessor Bankole Johnson,DSc, MD, MBChB, MPhil, DFAPA, FRCPysch, DAASCPGenesis Medical Director – Neuro & CognitiveMiami Stem Cell Clinic, Miami, FLFounder & Medical Directorwww.miamistemcell.clinicDisclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Timestamps 0:00 Intro0:52 Meet the Experts3:53 What is RPA?6:14 Limits of Current Treatments12:41 Steroids vs Healing13:42 Athletes vs Everyday Recovery16:50 Brain and Neuro Cases24:32 Evidence and Ethics25:57 Real Patient Results30:55 Autoimmune Effects32:10 Rapid Injury Recovery33:50 Avoiding Surgery Case35:50 How RPA is Delivered36:35 Broader Applications49:52 Vision Applications51:01 Safety vs Other Treatments56:00 Outro Hosted on Acast. See acast.com/privacy for more information.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics,  a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing and delivery strategy, workforce constraints, and building a clinical strategy around receptor positivity across tumor types. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

This week on Careers in Discovery, we're joined by Sarah Almond, VP of Translational Biology at NRG Therapeutics. Sarah shares her journey from early lab work to leading translational science on a first in class neurodegeneration programme. We talk about the serendipity that shaped her career, the importance of early hands-on experience, and how redundancies opened unexpected doors. Sarah reflects on leadership; from learning to give difficult feedback, to the responsibility that comes with shaping people's day to day wellbeing, to the power of listening when managing teams. She also discusses adapting to biotech's fast pace, navigating uncertainty, and the mindset needed to thrive in a small, mission driven environment.

Imagine being able to track your brain health before serious decline sets in, understand your personal risk factors, and intervene early enough to help prevent dementia rather than simply react to it.In this episode of The TechEd Podcast, Matt Kirchner talks with Christin Glorioso, MD, PhD, founder and CEO of NeuroAge Therapeutics, about one of the most intriguing frontiers in health and longevity right now: whether brain aging can actually be measured, influenced, and in some cases pushed back. If you've paid attention to the rise of biohacking, brain games, cognitive optimization, or the broader longevity movement, this conversation gets underneath the trend and into the science.Glorioso explains how brain MRI, cognitive testing, blood biomarkers, genetics, and AI can be used together to create a more individualized view of brain health. More broadly, the conversation shows how brain health is starting to shift from late-stage treatment toward earlier measurement, prevention, and ongoing optimization.In this episode:Why one of the biggest assumptions in dementia research may have been wrong for years  The 65% number that could completely change how you think about Alzheimer's riskWhy brain aging starts earlier than almost anyone realizes, and what that means for prevention  Whether you can actually make your brain younger, not just protect it from declineThe 9 daily factors that may matter more than any miracle supplement or trend  How AI is enabling faster research and more personalized interventionA roadmap for accessible tests + personalized recommendations for a healthier brain3 Big Takeaways from this Episode:1. Dementia is not one disease, and treating it like one has held the field back. Glorioso argues that Alzheimer's has been approached too narrowly for too long, with the pharmaceutical industry spending decades focused almost entirely on amyloid. Her point is bigger than one protein: brain decline is multifactorial, which means future progress will depend on earlier diagnosis and more personalized intervention.  2. Brain aging starts earlier than most people realize, but it is not a fixed downhill slide. In the episode, Glorioso says measurable shrinkage in the hippocampus begins in the mid-20s and accelerates with age. She also points to evidence that targeted exercise can increase volume in that same brain region, making the conversation far more hopeful than most people expect.  3. You're more in control of your brain health than you may realize. Glorioso cites research suggesting that up to 65% of Alzheimer's cases may be preventable through lifestyle interventions, then grounds that claim in concrete areas like exercise, sleep, stress, diet, metabolic health, and social connection. That turns brain health from an abstract fear into something people can measure, manage, and improve over time.Resources in this Episode:NeuroAge TherapeuticsFollow Christin on SubstackVisit the episode page for the rest of the resources: https://techedpodcast.com/glorioso/We want to hear from you! Send us a text.Instagram - Facebook - YouTube - TikTok - Twitter - LinkedIn

Recorded at the 2026 SCbio Annual Conference in Charleston, Heather and Matthew welcome Ken Webb, Professor of Bioengineering at Clemson University and Co‑Founder and President of NeuroHope Therapeutics. We have an exciting conversation about how Ken's research team is developing and commercializing novel drug‑delivery technologies aimed at treating central nervous system trauma, including spinal cord and traumatic brain injuries. Ken also reflects on his journey as an academic entrepreneur, the role of SCbio and other partners in supporting early‑stage life sciences startups, and what he sees ahead for innovation at the intersection of science and patient care. Tune in for insights on cutting‑edge research with a life-changing impact.

It was after an email exchange with Nobel Prize winning scientist Dr Kati Kariko, that Dr Anushi Rajapaska had a lightning moment and decided to back her research innovation – founding Mellbourne-based startup Misti to develop a ‘smart inhaler' based on acoustofluidics. It's engineered to deliver a wide range of biomolecules—including mRNA, antibodies, small molecules, and antigens. It's a first-in-class solution for both chronic and infectious respiratory conditions using super-sonic sound waves to generate ultra-fine aerosol for lung delivery of respiratory medications. While smart circuitry enables breath-triggered dosing and seamless digital integration.Anushi joins the podcast to talk about her 15 year innovation journey from PhD findings to setting up a global team connected to San Diego with a Victorian manufacturing base, the benefits of taking part in the JP Morgan Healthcare Week in early 2026 with Global Victoria's delegation and the connections she has forged.We also find out about her recent trip to BIO China in Suzhou where she took part in a panel discussion alongside MTPConnect CEO Stuart Dignam about how biotech startups can navigate cross-border collaboration between China and Australia. View preview of the episode!

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Listen to the podcast here

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Download the transcript here  

How terpenes, cannabinoids, and topical cannabis science helped an MS patient create a cannabis wellness brand. A deep dive into terpene-based cannabis medicine.

Dr. Mel O’Neal, Infectious Diseases pharmacist at Tampa General Hospital, presents part 2 of her series on Gram Negative Resistance, focusing on therapeutics for treatment of these resistant pathogens. Dr. O’Neal begins by identifying the main resistance mechanisms, including membrane porins, efflux pumps, drug binding site mutations, and degrading enzymes (e.g., beta-lactamases.) She then systematically covers the major agents used for treating resistant gram negative rods, including the newer beta-lactamase inhibitors, cefiderocol, and third-generation tetracyclines. Cases are also presented to emphasize the topics covered.

This week on Careers in Discovery, we're joined by Jonathan Levenson, CSO at FireCyte Therapeutics. Jonathan shares his unconventional journey from early curiosity about biology to a career spanning neuroscience research, Biotech innovation, and scientific leadership. We explore his transition from academia to industry, the lessons he learned building discovery platforms and leading translational programs, and how embracing storytelling and stakeholder alignment shaped his leadership approach. Jonathan also takes us inside the creation of FireCyte - from reimagining the retina as a window into neurodegeneration to navigating an early scientific pivot that reshaped the company's direction. His experience is a compelling reminder that breakthrough progress often starts with challenging assumptions and following the data.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Dr. Marc Hedrick, M.D., President and CEO at Plus Therapeutics, about the company's pivot from cell therapy to radiotherapeutics for brain cancers, and what's behind the choice of Rhenium-186 as the radioisotope for its lead development candidate, Reyobiq. We'll talk about Plus Therapeutics' diagnostic subsidiary, CNSide, and hear from Marc about recent FDA meetings and the agency's attitude toward novel radiotherapeutics.      Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

We love to hear from our listeners. Send us a message.On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company's strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye explains how trials, regulatory flexibility, and optimized manufacturing could make it possible to treat many genetic variants efficiently and cost-effectively. Ultimately, Aurora aims to build a repeatable model that expands gene editing access to larger rare-disease populations while keeping patients at the center of development.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion's partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

If you have liver problems, gut issues, or you're missing a gallbladder, Nurse Doza has a protocol built specifically for you. In this episode, he breaks down the Good Poops Protocol — three targeted supplements from MSW Nutrition that work together to support your gut, liver, and gallbladder function. Because here's the truth: your health starts in your gut, and when things are working the way they should, you'll know it — because you'll finally have good poops. Featured Partner: MSW Nutrition — The Good Poops Protocol The Good Poops Protocol from MSW Nutrition is a three-supplement system designed by Nurse Doza to address the interconnected health of your gut, liver, and gallbladder — even if you've had yours removed. It includes Liver Boost, Berberine Plus, and the Gut powder, each targeting a specific piece of your digestive health puzzle. If you've dealt with bloating, constipation, sluggish digestion, or been told your liver or gut "looks fine" when you know it isn't, this protocol was designed for exactly that.

David Southwell, CEO of Volastra Therapeutics, shares his insights about leadership in biopharma and how Volastra is working to discover and develop oncology therapeutics targeting chromosomal instability, a vulnerability of cancers.

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world's first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Send a textIn this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR's Healthcare Research Analyst, speak with Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY). The conversation explores Decoy's innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce explains how Decoy is navigating the modern era of drug development with a cost‑effective, highly efficient strategy that positions the company as a disruptive force in biotech. Central to this approach is Decoy' proprietary peptide‑synthesis technology and rapid design‑build‑test cycle, powered by machine learning. He also underscores the importance of Decoy's strategic partnerships with the Gates Foundation, Google, and NVIDIA in advancing its platform and accelerating development.

Goldman Sachs surging to fresh records as earnings top estimates, while some Mag7 stocks continue to struggle against the broader market. So will the big bank keep bumping, or can the big tech trouble make a turnaround? Plus the weight loss drug wars are heating up, with focus turning to the GLP-1 pill. The latest data from one pharma company, and what the CEO sees in store for the company as competition continues to climb.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.